We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Pharming

News List

Pharming’s APDS drug scores EU orphan status pharmatimes
October 22, 2020
Pharming’s investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been granted orphan drug designation from the European Commission.
Setback for Pharming’s bid to expand use of Ruconest pharmatimes
September 27, 2018
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis...
Pharming submits supplemental BLA to FDA for Ruconest for prophylaxis of hereditary angioedema attac pharmaceutical-business-review
November 28, 2017
Pharming Group has submitted a supplemental biologics license application to the US FDA for Ruconest for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.